Last reviewed · How we verify
YY2201
At a glance
| Generic name | YY2201 |
|---|---|
| Sponsor | Jiangsu YaYao Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YY2201 CI brief — competitive landscape report
- YY2201 updates RSS · CI watch RSS
- Jiangsu YaYao Biotechnology Co., Ltd. portfolio CI